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Abstract 
Cardiac biomarkers play a central role in myocardial injury and heart failure in adult patients 
however their clinical relevance in diagnosis and management in neonatology is not clearly stablished. The 
aim of this systematic review was to evaluate the recent literature on BNP/NTproBNP, Troponin I/T, 
CKMB and Myoglobin and their relationship with different pathologies of the newborn.  
A total of 67 articles were included to undergo data extraction, after a first text and abstract analysis 
and a second full-text analysis, using the PubMed database. 
Evidence show that cardiac biomarkers are a useful and fast diagnostic tool with great potential 
for becoming as important as clinical and echocardiographic findings in pathologies of the heart. 
BNP/NTproBNP and Troponin I/T demonstrated to be the ones with greater value. BNP/NTproBNP is of 
particular significance in the diagnosis and management of patent ductus arteriosus, as it has a good 
correlation with diagnosis, treatment and prognosis. Troponin T may be a beneficial additional marker for 
this disease, correlating with ductal significance and treatment response.  Moreover, BNP/NTproBNP can 
be used, with other clinical and laboratory findings, in the diagnosis and as a guide for treatment in 
pulmonary hypertension and in the diagnosis and management of cardiac sequela in bronchopulmonary 
dysplasia. Troponin I/T finds its clinical importance in perinatal asphyxia as a marker of myocardial injury 
and a reliable indicator of severity and mortality.  
Further studies with larger cohort populations are needed for stablishing the cutoff values specific 
for each neonatal pathology allowing its early and proper management. 
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Introduction 
Cardiac biomarkers reflect the structure and function of the heart, being widely used in the 
management of myocardial injury and heart failure in adult patients [1,2]. Their use in pediatrics, especially 
in neonatology, has been increasing but their clinical role as a guide for diagnosis, treatment and prognosis 
in neonatal diseases, is not clearly stablished and no current guidelines exist to guide their routine use [3,4]. 
B-type natriuretic peptide (BNP) and its inactive by-product N-terminal-pro-BNP (NTproBNP) 
are markers of volume expansion and pressure overload of the heart. BNP release results in improved 
myocardial relaxation and it antagonizes the response to the activated renin-angiotensin-aldosterone system 
[5]. The plasmatic half‐life of BNP is 20 min whereas for NTproBNP is 60 min [6]. BNP and NTproBNP 
can be simply measured with commercial kits including bedside tests, with good correlation between both 
biomarkers [7].  
Troponin (Tn) I and T, Creatine Kinase-MB (CKMB) and myoglobin are markers of cardiac injury 
[2]. The troponin complex, part of the sarcomere, regulates the cardiac and skeletal muscle contraction. It 
consists of three subunits: TnC (binds calcium ions and regulates the activation of actin filaments), TnI 
(inhibits muscle contraction in the absence of calcium) and TnT (binds troponin to tropomyosin and actin) 
[8]. TnC is not used as a marker of cardiac injury as it exists in highly homogenous isoforms whereas TnI 
exists only in three isoforms (one specific to the myocardium) and TnT has four isoforms specific to the 
cardiac muscle [9]. After a cardiac injury, troponins become detectable in the blood around the 2nd to the 
4th hour, with a peak at 12 hours and remain high for 7 to 10 days [10].   
CKMB is one of the three creatine-kinase isoenzymes expressed in the heart (≈22% of the total 
CK content) and skeletal muscle (≈1-3%). It is usually undetectable or in low levels in the blood except in 
the presence of both heart and skeletal diseases [11].  CKMB release in the blood after an injury is close of 
that of troponins, but its levels remain elevated for shorter time [12].  
Myoglobin is a cytoplasmic protein in striated cardiac and skeletal muscle with oxygen-carrying 
and reservoir function and a rapidly release after myocardial damage [11].   
Tn I and T show higher sensitivity and negative predictive value than CKMB in detecting 
myocardial injury [13] with CKMB and in particular myoglobin not offering additional diagnostic value in 
diagnosing for example acute myocardial infarction in adult patients [14].  
The aim of this systematic review was to evaluate the recent literature on Cardiac Biomarkers 
(BNP/NTproBNP, TnI/T, CKMB and myoglobin) and their relationship with different pathologies and 
diagnosis in Neonatology. 
 
 
Methods 
Protocol 
A review was conducted based on the Preferred Reporting of Systematic Reviews and Meta-
Analysis (PRISMA) guidelines. 
 
Eligibility Criteria 
Clinical trials, prospective and retrospective observational studies aiming the use of cardiac 
biomarkers in neonatology were considered. Measurements of the biomarkers BNP/NTproBNP, TnI/T, 
CKMB and Myoglobin in the cord blood, arterial and venous blood were included. Neonates with or 
without pathology were considered. Pathologies diagnosed prior to birth or conditions affecting the neonate 
in intrauterine life were not the purpose of this review.  
Studies with these biomarkers levels in neonates without disease versus with disease were 
addressed, as the use of these biomarkers versus actual diagnostic methods or its inexistence in neonatal 
age, in newborns with pathology. 
Records from January 1990 to June 2016 were considered. The search strategy was restricted to 
studies concerning human subjects that were available in the English language. Data concerning 
simultaneously neonates and children/adult patients were included, unless the neonates group were not 
separated from the rest of the groups studied.  
Duplicate articles, comments, case series, narrative or systematic reviews and meta-analyses, as 
well those not related with the purpose of the study were excluded. 
Information sources 
On June 1, 2016, a PubMed literature search focused on cardiac biomarkers in neonatology was 
executed. The following MESH terms and text key words were used: “natriuretic peptide, brain” or “pro-
brain natriuretic peptide” or “troponin i” or “troponin t” or “myoglobin” or “creatine kinase, mb form” and 
“infant, newborn” or “neonatology”. 
 
Study Selection 
First analysis included a screening of all article titles and abstracts to identify relevant studies.  
References were crosschecked in all selected articles, to identify articles missed by the initial search 
strategy, using the same inclusion and exclusion criteria. 
Eligibility was assessed by 2 authors (R.P.T. and A.L.N.) in all potentially relevant articles. 
Disagreements were resolved by discussion. 
 
Data items 
Data were extracted on type of pathology, cord/plasma biomarkers levels and age. When reported 
in the study, type and biomarkers concentrations of controls and correlation to echocardiographic 
measurements were collected. 
 
Summary measurements and synthesis of results 
The principal summary measures included mean cord/plasma biomarkers levels, grade of 
correlation and risk ratio. Data from different studies were registered, then combined, and summarized 
according the type of biomarker. 
 
 
Results 
 
Study selection 
A detailed flowchart of the systematic review is presented in Figure 1. Through PubMed searching 
373 articles were identified. After duplicates removed, 372 articles were included in the first analysis: 
screening of the reference list based on their titles and abstracts. This step was crosschecked between the 
two researchers. After the first step, 273 articles were excluded based on the title and abstract: 27 articles 
did not include a group of only neonates; 22 articles did not focus on pathologies diagnosed after birth; 2 
articles were animal studies; 34 articles were comments, reviews or case series and 188 articles did not 
address our outcomes of interest. A total of 5 articles were not assessed, since we did not have access to 
full text. Therefore, 94 full-text retrieved articles were carefully assessed. From these, 27 were excluded 
based on our previously defined exclusion criteria: 7 articles did not include a group of only neonates and 
20 articles did not address our outcomes of interest. In the end, 67 articles were included to undergo data 
extraction. 
 
Study characteristics 
  Study characteristics are summarized in the Table 1. Prospective and retrospective case-controls 
studies and cohort studies were included. Most of the studies were single-center and with an observation 
period from at least one year, including studies from different countries such as USA, Italy, UK, Ireland, 
Korea, Thailand, Portugal, India and others. 
 
Results of individual studies 
 
BNP and NTproBNP 
BNP/NTproBNP in Patent Ductus Arteriosus  
Several studies concerning BNP and NTproBNP in neonatology focused on their potential role in 
patent ductus arteriosus (PDA). BNP concentrations were significantly higher in preterm neonates with 
echocardiographically proven PDA (p<0.001) [15,16] and no difference was observed between term and 
preterm without PDA [16]. Higher levels of BNP correlated with increasing magnitude of the PDA [17,18]. 
In fact, in infants with an hemodynamically significant patent ductus arteriosus (hsPDA) (defined by a left 
atrial/aortic root (LA/Ao) ratio >1.5 and a ductal diameter >1.4mm on echocardiography [15]), mean BNP 
levels were significantly higher than those with either no hsPDA [19,20] or non PDA (p<0.005)  [19,21]. 
Moreover, a study concerning hemodynamically significant left-to-right (hsLtR) shunts as a group, found 
that BNP concentrations were significantly more elevated in neonates with hsLtR shunts compared to 
cyanotic heart disease or no heart disease (p<0.0001). However infants with hsPDA had significantly higher 
levels of BNP compared to the rest of hsLtR shunts (p=0.016) [22].  
Mean BNP correlated positively with echocardiographic magnitude of the ductal shunt: ductal 
diameter, LA/Ao ratio and diastolic flow velocity of the left pulmonary artery [15,18,20,21]. The LA/Ao 
ratio was the mostly related parameter to BNP concentration in the newborns [16].  
BNP concentrations were positively correlated with the need of ductus intervention and not only 
to the presence of PDA. In addition to ductal diameter  >1.5 mm, BNP had the best predictive value (PPV): 
91% for the need of treatment [23]. Also significant differences in levels of BNP were demonstrated with 
increasing ventilatory support [17]. A study showed that a BNP level more than 250 pg/mL at day 2 
indicated the need of medical treatment (OR=5.0) and that above 2000 pg/mL within the first 5 days 
indicated the need of surgical correction (OR=52.2) [24]. Moreover, successful closure was reflected by a 
corresponding decrease in BNP [15,19] and BNP concentrations on days 3, 5 and 7 remained higher in 
infants with persisting PDA [15].  
Regarding NTproBNP, studies showed main results similar to BNP results.  In newborns with a 
PDA, NTproBNP levels were significantly higher compared to those with spontaneous PDA closure, 
(p<0.001) [25] and they could identify neonates with a high risk of developing an hsPDA from day 1 to 7 
[26-29]. Moreover, low levels of NTproBNP could detect neonates with a closed ductus [26] and higher 
levels could identify those with later treated or persistent PDA [30]. Additionally, NTproBNP levels were 
significantly elevated in a PDA that could later develop severe intraventricular hemorrhage or death 
compared to a PDA without complications [25].  
NTproBNP correlated with echocardiographic flow patterns as those above mentioned for BNP 
[26,29-31] and successful ductus closure was also correspondent with a decline in NTproBNP levels  
[27,32]. In fact, a study using a predetermined cutoff level of NTproBNP [32] showed that using its levels 
on day 2 to guide early treatment with indomethacin reduced later onset of hsPDA, neither reopening of 
ductus or PDA ligation and reduced the exposition to indomethacin, only 11% [33]. Accordingly, 
NTproBNP on day 3 could predict whether a neonatal physician blinded to results would treat a PDA [27].  
A study comparing both biomarkers stated that BNP and NTproBNP seem to be similarly useful 
in the diagnosis of PDA and evaluation of its magnitude in preterm neonates. Correlation with PDA size 
for BNP was r=0.35 (p=0.0066) and for NTproBNP was r=0.31 (p=0.018) [34].  
The cutoffs levels proposed from different studies to diagnose an hsPDA of both BNP and 
NTproBNP are described in Table 2, with respective area under the curve, sensitivity, specificity, positive 
and negative predictive value. 
 
BNP/NTproBNP in Congenital Heart Defect 
A study revealed that BNP values were significantly higher (p<0.001) in the whole group of 
congenital heart defect (CHD) patients than in controls but considering the different CHD groups 
separately, all groups, except for of right ventricular pressure/volume overload, showed significantly higher 
values compared to control group (P≤0.0001). The authors attribute the difference in the groups to the low 
number of patients in the right ventricular pressure/volume overload group [35].  
In a different study with neonates undergoing surgery for CHD, the preoperative BNP levels were 
higher in infants with CHD, compared with age-matched controls (p<0.001), with a good diagnostic 
accuracy. A cutoff value of 363.5 pg/mL had a sensitivity of 87.4%, a specificity of 87.6% for diagnosing 
CHD. BNP values were higher than older children values, and differently from them, they decreased 
immediately after surgery [36]. 
In critical CHD infants with ductal-dependent systemic circulation BNP levels were markedly 
elevated in the presence of cardiogenic/circulatory shock [37]. Besides, cord blood BNP was significantly 
higher in infants with hypotension and cardiac dysfunction treated with dopamine than in infants without 
dopamine administration. A cutoff values of >90 pg/L yielded a sensitivity of 68% and specificity of 84%, 
for identifying neonates who required dopamine administration after birth [38]. 
Concerning NTproBNP, their levels in the cord blood were higher in neonates with CHD [39,40] 
and this was especially evident in the right ventricular outflow tract obstruction without ventricular septal 
defect group. Additionally, elevated NTproBNP levels were indicators of functional single ventricle 
(substantially increased) and in neonates with CHD it was noted a marked increase of their levels in the 
first week of life [40]. A study with a 1-year follow-up showed that cord blood NTproBNP was associated 
with 1-year survival [39]. 
NTproBNP correlated with echocardiography measurements, namely LA/Ao ratio and a less 
significant negative correlation between NTproBNP and left ventricular function [41]. 
A study concerning cardiac neonatal lupus showed that median cord blood NTproBNP levels were 
higher in cardiac neonatal lupus cases than in unaffected fetuses and positively associated in a multivariate 
analysis (p=0.04) including as covariates maternal IV Ig/hydroxychloroquine, steroid exposure at birth and 
week of delivery [42].  
 
BNP/NTproBNP in pulmonary hypertension  
A study demonstrated a positive correlation between mean pulmonary artery pressure and BNP 
levels (r=0.643, p<0.0001) [43] . BNP values were higher in infants with persistent pulmonary hypertension 
(PH) relative to controls (neonates with non-cardiac causes of respiratory distress (RD) and neonates 
without RD). BNP levels correlated with echocardiographic parameters of PH such as the gradient of the 
tricuspid regurgitation jet and the ratio of tricuspid regurgitation jet gradient to mean blood pressure [44]. 
In infants with persistent PH with criteria for inhaled NO (iNO) therapy, initial BNP levels above 30 ng/dL 
showed excellent sensitivity 100% and negative predictive value 10%  for predicting the subsequent need 
for iNO [45] 
For NTproBNP, a correlation to estimated pulmonary mean pressure (r=0.45; p=0.03) and to the 
diastolic impairment signs of PH in the echocardiography: global right ventricle function (RV Tei index) 
and tricuspid E/A ratio was also found [46]. In term neonates with RD,PH was associated with significantly 
higher NTproBNP (p<0.001), irrespective of its etiology: CHD or pulmonary disease [47]. Moreover, in 
neonates with PH, early elevations in NTproBNP levels were observed in non-survivors, significantly 
higher than survivors [46].  
 
BNP/NTproBNP in Respiratory Distress, Bronchopulmonary Dysplasia and Transient 
Tachypnea of the Newborn  
In infants with RD, the median BNP concentration was significantly elevated in the ones with 
CHD compared to non-CHD group (p<0.001) and showed to have a good sensitivity and negative predictive 
value to exclude serious cardiovascular problems in neonates with RD. However, not all CHD were 
associated with ventricular stress and raised BNP levels [48] 
Concerning NTproBNP, neonates with RD had significantly higher NTproBNP (p<0.04) [41,47], 
showing a different time course according to the underlying disease. On the first day of life, NTproBNP 
could not differentiate according to the underlying disease but from the second day of life onwards, 
NTproBNP enabled differentiation between CHD or other than cardiac reasons (respiratory disorder or 
perinatal asphyxia) [49]. In opposition, a study with term neonates with RD, NTproBNP levels were not 
significantly different according to the etiology: CHD or pulmonary disease [47]. 
About Bronchopulmonary Dysplasia (BPD), BNP is significantly higher in preterm infants with 
this condition and it correlates with BPD severity: significantly elevated in severe BPD compared to 
moderate and mild BPD (p<0.001) [50].  
NTproBNP levels were also more elevated in newborns with RD who developed BPD and in the 
non-survivors ones (p<0.001). These findings were demonstrated in both infants with a diagnosis of PDA 
(p<0.001) and in infants without (p<0.05) [51] . Accordingly, in preterm who developed BPD, NTproBNP 
concentrations were significantly higher than preterm without BPD and healthy term. Concentration of 
NTproBNP positively correlated with severity of RD, independently with BDP only, while taking into 
account 5-minute Apgar scores, gestational age and birth weight as potential confounders (p<0.002) [52]. 
Regarding transient tachypnea of the newborn (TTN), a study in 2012, noted that the mean 
NTproBNP concentrations in neonates with TTN were significantly higher than in controls at the 6th, 24th, 
72th and 120th of life (p<0.001) and there was a moderate correlation between concentrations at 24 hours 
and duration of tachypnea (r: 0.41, p=0.001). Moreover, a cutoff value of >6575 pg/ml NTproBNP at 24 h 
showed a sensitivity of 85% and specificity of 64% to predict mechanical ventilation support [53]. One 
year after, a more recent study, showed that the average of NTproBNP levels did not differ significantly 
between the study group with TTN and controls [54]. No studies were found aiming BNP in TTN. 
 
Troponin I/T 
Troponin I/T in Perinatal Asphyxia and Hypoxic Ischemic Encephalopathy 
Several studies showed that TnT levels were more elevated in infants with perinatal asphyxia 
compared to controls, in the cord blood (p<0.01) and at 3rd, 6th, 12th, 24th and 48th hours (p<0.001) [55-61]. 
The periods when specificity and sensitivity were highest together were the 12th and 24th hours [55]. These 
values decreased at 48th and 72th hours[57]. TnI values were also significantly higher in infants with 
perinatal asphyxia [62,63] correlating positively with the traditional markers of asphyxia as arterial 
umbilical pH and bicarbonate, base deficit and Apgar score [62]. This correlation was not present at 12 
hours  of life [63]. 
A Nigerian study with negroid neonates also showed TnT levels significantly higher in 
asphyxiated infants but significantly higher in deliveries assisted by vacuum or forceps, contrasting with 
studies in developed countries where TnT levels were not affected by mode of delivery [64].  
In neonates with moderate to severe asphyxia TnT levels were significantly higher in the presence 
of myocardial injury [58,65,66] with levels being higher in severe asphyxia compared to mild and no 
asphyxia [57,58,67]. On day 3 and 7, TnT levels remained high in neonates with severe perinatal asphyxia 
[67]. No significant difference was detected between neonates with mild asphyxia and controls [57].  
TnT levels correlated with echocardiographic findings of myocardial dysfunction [56,57,66] as it 
correlated positively with the left and right ventricle Tei index [56], stroke volume and left ventricular 
output [66] and negatively with the mitral and tricuspid systolic (Sm) velocity [56]. Systolic and diastolic 
functions were generally preserved in asphyxiated infants but the reduction of the left ventricular output 
and stroke volume suggested a sub clinical myocardial injury [66]. 
Moreover, TnT levels were significantly higher in hypotensive neonates needing inotropic 
support/catecholamine [56,61], in the ones who develop congestive cardiac failure [60] and in the non 
survivors [25,56,58,60], with a cutoff of 0.15 µg/l, giving a specificity of 100% and a sensitivity of 70% to 
predict mortality [56].  
Several studies also showed that infants with perinatal asphyxia who developed hypoxic ischemic 
encephalopathy (HIE) had raised TnI levels with increasing severity of HIE, being strongly correlated with 
its clinical grade [38,68,69]. TnI concentrations at 36 h of life correlated strongly with duration of inotropic 
support [68] and the non-survivors had significantly high raised levels of TnI in comparison to survivors 
[38,68,69]. A cord blood level of 4.6 ng/ml was found to be the optimal cutoff level in predicting early 
mortality with a sensitivity: 77% and specificity: 97%, showing a higher specificity, positive predictive 
value and AUC than arterial umbilical base deficit and 5 minute Apgar [69]. 
 
Troponin I/T and Cardiac Dysfunction  
Studies showed that TnT is as a marker of myocardial contractility reflecting the degree of 
myocardial compromise as it correlates with echocardiographic markers of myocardial function and stroke 
volume [41,66,70]. No correlation was found with left and right ventricular output [41]. 
A study with infants of diabetic mothers, TnI levels were significantly higher in left ventricular 
dysfunction and/or hypertrophic cardiomyopathy being as sensitive as echocardiographic measurements in 
the detection of cardiac dysfunction [71]. 
In a study with extremely low birth weight infants, TnT levels were higher in the ones with cardiac 
dysfunction who needed inotropic support for persistent hypotension in the first 48h after birth. The authors 
suggested that these values, in cord blood or in the first hours of life, could be an indicator to early 
cardiovascular support before clinical signs of hypotension appear [72]. 
 
Troponin I/T in Congenital Heart Defects 
TnT concentrations in neonates with CHD were significantly higher than healthy controls. 
However, there was no correlation between its levels and clinical signs of heart failure, echocardiographic 
markers of left ventricular compromise or type of heart defect. TnT levels correlated positively with the 
hemodynamic significance of CHD (p=0.048) [73].  
In a study with infants undergoing cardiac surgery for CHD, preoperative TnI was elevated in all 
neonates undergoing cardiac surgery with cardiopulmonary bypass: hypoplastic left-heart syndromes and 
transpositions of the great arteries, with or without ventricular sept defect compared to controls: Blalock-
Taussig shunt and coarctation of aorta [74].  In opposition, a study also with TnI did not find significant 
differences between healthy and CHD groups or between groups of CHD, neither between the need of 
conservative versus surgical treatment [75]. 
 
Troponin I/T in Patent Ductus Arteriosus 
Studies showed that TnT levels at the 48th of life were significantly higher in preterm with 
persistent PDA compared to those with spontaneous closure (p<0.001) [25,76]. A significant correlation 
was found between TnT levels and echocardiographic parameters: ductal diameter, LA/Ao ratio, and 
descending aortic end-diastolic velocity. A cutoff of 0.20 µg/L yielded a sensitivity of 70% and a specificity 
of 75% to diagnose PDA. Following successful treatment, TnT levels decreased significantly (p<.001) [76]. 
In opposition, another study, found no correlation between PDA LA/Ao ratio and TnT [41]. As NTproBNP, 
TnT levels were significantly higher in a PDA that could later develop severe intraventricular hemorrhage 
or death compared to a PDA without complications [25]. No studies were found concerning TnI and PDA. 
 
Troponin I/T in Respiratory Distress 
Several studies showed that newborns with RD had significantly higher TnT (p<0.01) compared 
to controls [41,59,70,77-80] and these concentrations were positively correlated to oxygen requirement 
[78], duration of ventilatory support [77] and to the need of inotropic support [70,78]. In addition, the 
infants who later died tended to have higher TnT levels than the ones who survived [78,80]. 
Accordingly, in a study with ventilated infants with idiopathic moderate to severe RD syndrome 
they had significantly higher TnI levels than healthy infants (p<0.05), with the ones with severe RD 
showing higher TnI  levels than moderate RD ones (p<0.05) [81]. 
 
CKMB 
CKMB in Perinatal Asphyxia and Hypoxic Ischemic Encephalopathy 
Several studies demonstrated that CKMB levels in neonates with perinatal asphyxia were 
significantly higher in the cord and venous blood samples when compared to controls [55,59,62,67]. 
Specificity for cardiac damages increased from 50% in the cord blood to 96% at 24 hours, whereas 
sensitivity decreased from 86% in the cord blood to 40% at 24 hours. A positive correlation was found 
between the TnT and  CKMB values at the 6th and 12th hour, however, no correlation could be found  at 
the 3rd and 24th hour [55]. The best cutoff found for CKMB in a study had lesser sensitivity and specificity 
than TnT to predict myocardial damage but more value than echocardiographic examination [59]. CKMB 
levels also correlated with severity, being significantly higher in asphyxia grade II and III than grade I and 
healthy controls within the first 2 to 4 hours. These differences were not found on day 3 [67].  
In infants with asphyxia, CKMB concentrations are elevated in the presence of myocardial injury, 
acute kidney injury or both [65]. 
In term infants with perinatal asphyxia who later developed to HIE, CKBM levels were raised but 
with less sensitivity and specificity than TnI [38,62,69] and no relationship with cardiac dysfunction, 
severity and mortality [38,69]. Also, CKMB had a correlation with mode of delivery, gestational age and 
birth weight [62]. 
 
CKMB in Congenital Heart Defect 
There was no significant difference in CKMB levels between healthy and CHD neonates or 
between groups of CHD. However levels of CKMB were elevated in patients with CHD who had surgery 
correction in the hospitalized neonatal period than in those discharged without surgery (p<0.05) with a 
cutoff of >4.6 ng/mL demonstrating a sensitivity of 87.5% and specificity of 63.6% for predicting surgery. 
Moreover, CKMB correlated negatively with echocardiographic measurements of diastolic function as 
mitral valve lateral annulus peak early/late diastolic velocity ratio [75]. 
 
Myoglobin 
Myoglobin in Congenital Heart Defect 
Myoglobin levels were not significantly different between healthy and CHD groups or between 
groups of CHD, neither between conservative treatment or surgical groups with CHD [75]. 
 
Synthesis of results 
The synthesis of the results stated above are summarized in table 3.  
Studies showed significantly higher levels of BNP/NTproBNP in PDA [15,16,25], CHD 
[35,36,39], PH [43,46], RD [41,47,48] and BPD [50-52]. In TTN, different studies showed opposing results 
[53,54].   
BNP/NTproBNP in PDA correlated with echo measurements [15,20,21,25,26,29-31], the presence 
and severity of an hsPDA [19-21,26-29], the need for treatment [23,24,27,30] with decreasing levels after 
successful closure [15,19,27,32], complications and mortality [25]. Different cutoffs could be used to 
determine hsPDA (table 2) for both BNP and NTproBNP as their role seem to me similarly useful [34].   
BNP/NTproBNP in critical CHD infants with ductal-dependent systemic circulation were 
markedly elevated in the presence of cardiogenic/circulatory shock [37] and could be used for detecting 
infants who required dopamine administration in the first hours of life [38].  
In PH, BNP/NTproBNP concentrations correlated with echocardiographic parameters of PH 
[43,44] and to the diastolic impairment associated [46]. In a study with infants with persistent PH, BNP 
showed good sensitivity and negative predictive value for predicting the subsequent iNO requirement [45]. 
NTproBNP correlated also with mortality [46].  
About BNP/NTproBNP in RD, studies showed different results in the role of this biomarker to 
identify the etiology of the RD, despite its good sensitivity and negative predictive value to exclude serious 
cardiovascular problems. NP/NTproBNP levels correlated with BPD severity and mortality [50-52].  
Studies concerning TnI/T demonstrated its higher concentrations in perinatal asphyxia and 
HIE[55-61] [62,63], Cardiac dysfunction [41,66,70,71], CHD (only TnT) [73,74], PDA (only TnT)  [25,76] 
and RD [41,59,70,77-80].  
In perinatal asphyxia, TnI/T levels correlated with echocardiographic findings of myocardial 
dysfunction [56,57,66], severity [57,58,67], congestive heart failure [60], the need of inotropic 
support/catecholamine [56,61] and mortality [25,56,58,60]. Neonates with perinatal asphyxia who 
developed HIE had raised TnI levels, correlated also with severity of HIE, its clinical grade and mortality 
[38,68,69]. 
TnT in CHD despite its high levels, there was no correlation between its levels and clinical signs 
of heart failure, echocardiographic markers of left ventricular compromise or type of heart defect [73]. 
Studies with TnI in CHD showed opposing results [74,75].  
In PDA, studies focusing on TnT showed different results concerning its correlation with 
echocardiographic measurements [41,76] but a positive correlation with complications and mortality [25]. 
No studies were found concerning TnI and PDA. 
TnT in RD correlated with oxygen requirement [78], duration of ventilatory support [77], the need 
of inotropic support [70,78] and mortality [78,80], as TnI correlated with RD severity [81]. 
Regarding CKMB, studies demonstrated its high levels in perinatal asphyxia and HIE 
[38,55,59,62,67,69] and CHD [75].  
CKMB in perinatal asphyxia correlated with echocardiographic findings of myocardial injury and 
severity but with lesser sensitivity and specificity than TnT to predict myocardial damage as it is influenced 
by several factors such as the presence of kidney injury, mode of delivery, gestational age and birth weight 
[62,65]. In HIE, CKMB had no relationship with cardiac dysfunction, severity and mortality [38,69]. 
In CHD, there was no significant difference in CKMB levels between controls and CHD neonates 
but its levels were higher in neonates with CHD who had surgery correction in the hospitalized neonatal 
period than in those discharged without surgery [75]. 
About Myoglobin, there was only one study found with no relevant results in CHD. Their values 
showed no significant difference between healthy and CHD groups or between groups of CHD, neither 
between conservative treatment or surgical groups with CHD. 
 
Limitations of individual studies 
 Different studies addressed in this article find similar limitations in their study design, namely 
concerning the low number of the population studied and the difficulty to find a group of healthy neonates, 
especially if they only consider preterm. Besides, the quantity of blood for analysis must to be the least 
possible, differing from test to test and making it hard to evaluate the evolution of some biomarkers across 
time. Other mentioned limitation was the vascular accesses difficulty in some neonates with less birth 
weight or with a life-threatening condition that had to be prioritized.   
 
 
Discussion 
 
Summary of evidence 
Main studies concerning BNP/NTproBNP centered its role in PDA. Evidence show that due to the 
good correlation between NTproBNP/BNP levels and echocardiographic PDA parameters, these peptides 
represent a useful diagnostic tool, with good sensitivity and specificity, in the diagnosis of an hsPDA. These 
levels can be used to guide physicians to consider early echocardiographic evaluation or in its absence to 
transfer the newborn to a proper place with pediatric cardiology facilities. Using certain cutoffs, it could be 
possible to identify the ones who require an early and individualized therapy. In the other hand, low levels 
may aid in the recognition of neonates with a closed ductus or a PDA that would most likely close 
spontaneously, reducing overtreatment. In addition, as its levels decreases with ductal closure, 
NTproBNP/BNP can be useful for monitoring efficacy of treatment. The considerably variation of the 
different cutoff values to diagnose hsPDA, was a consequence of the different assay methods (not addressed 
in this study) and to the time of the blood sampling. 
The evidence does not define a role for BNP/NTproBNP in CHD, as not all defects are associated 
with ventricular stress and elevated BNP/NTproBNP values. 
Concerning PH, despite its good correlation to echocardiographic findings, BNP/NTproBNP 
clinical relevance needs further studies. In combination with other clinical and laboratory information, these 
markers could be used to help diagnose persistent PH, especially in a care facility with limited access to 
pediatric echocardiography and as a guide for early pulmonary vasodilator therapy or even transfer to an 
extracorporeal membrane oxygenation  center in newborns with more serious disease and worse prognosis. 
In RD, BNP/NTproBNP demonstrated its greater importance in BPD. Its levels are higher in BPD 
with strongest correlation in neonates with PDA but also in newborns with no PDA and evidence also show 
correlation with clinical severity of respiratory disease. These findings suggest that using this biomarker 
could help in a better diagnosis and management of myocardial sequela of BPD. 
 Evidence demonstrate that TnI/T level is a useful tool for showing cardiac damage in neonates 
with perinatal asphyxia. Its sensitivity and specificity are much higher than echocardiography and other 
biomarkers such as CKMB, while the implementation of the method is simple. Moreover, it is a reliable 
indicator of severity and mortality. This early detection of myocardial damage could improve the 
management and survival of these infants, providing proper cardiovascular support besides managing the 
primary condition. 
TnI/T, though it has high concentrations in CHD, it is independent of the type of heart defect and 
there is no correlation between its levels and clinical signs of heart failure or echocardiographic markers of 
left ventricular compromise. It may be useful as a marker of myocardial contractility. Further studies are 
required to explore its application. In PDA in particular, TnT may be valuable in evaluating ductal 
significance and response to therapy, due to its correlation with echocardiographic flow patterns. These 
raised levels may reflect the potential cardiac injury caused by a PDA and TnT measurements may identify 
infants at risk for PDA associated myocardial ischemia that would benefit from early treatment. In fact, 
evidence show that BNP/NTproBNP and TnT in addition to echocardiographic findings may guide future 
trials of targeted medical treatment in neonates with a PDA, namely neonates with higher risk of severe 
complication who may benefit from an early and individualized therapy. 
Regarding TnT in RD, evidence show that this biomarker is also a useful and specific marker for 
myocardial injury in newborns with RD. Its concentrations could be used to guide treatment and manage 
the evolution of this condition, as it correlates with severity and mortality. 
CKMB as referred above does not seem to be specific enough to be of clinical value, being less 
specific and sensitive for myocardial injury than TnI/T. 
Myoglobin is the least studied cardiac biomarker with only one article meeting the criteria for this 
revision.  
 
 Limitations 
 Although it is a systematic review, it is still difficult to locate all the studies concerning the subject. 
Only PubMed was used as a database and despite our best efforts, some articles were not assessed, once we 
did not have access to full text. Besides, some studies with pediatric populations included neonates but they 
did not perform analysis in a group only with neonates, being excluded. 
 
Conclusions 
Cardiac Biomarkers are a useful and fast diagnostic tool that have great potential in the 
management of neonatal patients and for becoming as important as other diagnostic tests in pathologies of 
the heart. BNP/NTproBNP and TnI/T seem to be the ones with greater value. 
BNP/NTproBNP can be used in the diagnosis and management of PDA, as it has a good correlation 
with diagnosis, treatment and prognosis. The cutoff for diagnosing hsPDA must be established according 
to the type of biomarker, gestational age and assay method. TnT may be a beneficial additional marker for 
this disease, correlating with ductal significance and treatment response. Moreover, BNP/NTproBNP can 
play a significant role, with other clinical and laboratory findings, in the diagnosis of PH and as guide for 
treatment in this condition and in the diagnosis and management of myocardial sequela in BPD. 
TnI/T finds its clinical relevance in perinatal asphyxia as a marker of myocardial injury and a 
reliable indicator of severity and mortality. 
Further studies with larger cohort populations are needed for stablishing the right cutoff values 
specific for each neonatal pathology allowing its early and proper management. 
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Table 1 Studies characteristics 
Type of 
Study 
Publication 
Date 
City, 
Country 
Population Study 
Period 
Main outcome Reference 
Observational  2004 London,  
UK 
18 preterm <34weeks  
11 healthy term controls 
5 months BNP in PDA [15] 
Observational 2010 Pavia,  
Italy 
36 preterm <35weeks 
34 healthy term 
1 year  
4 months 
BNP in PDA [16] 
Prospective 
observational 
2006 New York, 
USA 
19 preterm <32 weeks 9 months BNP in PDA [17] 
Observational 2005 New York, 
USA 
20 preterm <36weeks Not 
mentioned 
BNP in PDA [18] 
Retrospective 
observational 
2013 Seoul, 
Korea 
73 extremely low birth 
weight 
7 years  
5 months 
BNP in PDA [21] 
Prospective 
observational 
2005 Detroit, 
USA 
29 preterm <34weeks 11 months BNP in PDA [19] 
Prospective 
observational 
2005 Seoul, 
Korea 
66 preterm <34weeks 
 
1 year  
3 months 
BNP in PDA [20] 
Prospective 
observational 
2011 Patras, 
Greece 
75 neonates with 
suspected CHD 
Not 
mentioned 
BNP in LtR shunts 
and PDA 
[22] 
Prospective 
blinded 
clinical 
2008 Berlin, 
Germany 
67 preterm <28 weeks 1 year  
8 months 
BNP in PDA [23] 
Retrospective 
observational 
2013 Osaka, 
Japan 
46 preterm 2 years  
9 months 
BNP in PDA [24] 
Observational 2008 Dublin, 
Ireland 
80 preterm <32weeks or 
<1500g 
1 year  
1 month 
NTproBNP and 
TnT in PDA 
[25] 
Prospective 
observational 
2014  Rome,  
Italy 
41 preterm <32 weeks 1 year  
8 months 
NTproBNP in PDA [26] 
Blinded 
prospective 
2009 London,  
UK 
100 preterm <34weeks 2 years  
1 month 
NTproBNP in PDA [27] 
Prospective 
observational 
2008 Dublin, 
Ireland 
49 preterm <34 weeks 9 months NTproBNP in PDA [28] 
Prospective 
observational 
2011 New Jersey, 
USA 
52 preterm <34 weeks or 
<1250g 
1 year  
1 month 
BNP in PDA [29] 
Blinded 
prospective 
2011 Brussels, 
Belgium 
31 preterm <32 weeks or 
< 1500g 
1 year NTproBNP in PDA [30] 
Prospective, 
cross-
sectional 
2012 Zurich, 
Switzerland  
218 neonates and infants 
with CHD 
222 healthy age-matched 
controls 
3 years BNP in CHD [31] 
Observational 2009 Bangkok, 
Thailand 
35 preterm <33 weeks 1 year  
1 month 
NTproBNP in PDA [32] 
Interventional 2011 Bangkok, 
Thailand 
50 preterm <33 weeks 1 year NTproBNP in PDA [33] 
Prospective 
observational 
2015 Melbourne, 
Australia 
58 preterm <32 weeks Not 
mentioned 
BNP and 
NTproBNP in PDA 
[34] 
Observational 2011 Massa,  
Italy 
218 neonates and infants 
with CHD 
222 healthy age-matched 
controls 
3 years BNP in CHD [35] 
Prospective 
observational 
2013 Pisa,  
Italy 
336 children with CHD 
(87 neonates) 
436 healthy controls 
2 years  
4 months 
BNP in CHD [36] 
Cohort 2012 Atlanta, 
USA 
122 infants with ductal-
dependent systemic 
circulation 
4 years  
5 months 
BNP in CHD [37] 
Prospective 
observational 
2012 Dharan, 
Nepal 
60 term with perinatal 
asphyxia who developed 
to HIE 
11 months TnI and CKMB in 
HIE 
[38] 
Prospective 
observational 
2015 Daegu, 
Korea 
76 neonates with CHD 
45 healthy controls 
4 years  
5 months 
NTproBNP in CHD [39] 
Prospective 
observational 
2009 Linz, 
Austria 
60 neonates with CHD 
200 control subjects 
2 years  
8 months 
NTproBNP in CHD [40] 
Prospective 
observational 
2008 Dublin, 
Ireland 
80 neonates <1500g 11 months TnT and 
NTproBNP in 
Cardiac 
Dysfunction 
[41] 
Cohort 2015 New York, 
USA 
139 anti-SSA/Ro-
exposed fetuses 
Not 
mentioned 
NTproBNP in 
cardiac neonatal 
lupus 
[42] 
Observational 1996 Tokyo, 
Japan 
10 infants <36 weeks 1 year BNP and pulmonary 
arterial pressure 
[43] 
Prospective 
cohort 
2004 Lexington, 
USA 
15 neonates with 
persistent PH 
17 neonates with RD 
15 healthy neonates  
1 year BNP in PH [44] 
Prospective 
observational 
2015 Detroit, 
USA 
19 term with persistent 
PH 
Not 
mentioned 
BNP in PH [45] 
Prospective 
observational 
2008 Porto, 
Portugal 
18 neonates with CHD 
10 healthy age-matched 
controls 
1 year 
9 months 
NTproBNP in PH [46] 
Prospective 
observational 
2014 Belgrade, 
Serbia 
62 neonates with RD 1 year  
1 month 
NTproBNP in RD [47] 
Prospective 
observational 
2008 Seoul, 
Korea 
73 term neonates with 
RD 
1 year  
8 months 
BNP in RD [48] 
Prospective 
observational 
2013 Linz, 
Austria 
40 neonates with arterial 
duct-dependent CHD 
40 neonates with RD 
without CHD 
2 year  
8 months 
NTproBNP in RD [49] 
Prospective 
case-control 
observational 
2014 Michigan, 
USA 
60 preterm <32 weeks Not 
mentioned 
BNP in BPD [50] 
Cohort 2015 Aarhus, 
Denmark 
134 preterm <32 weeks 1 year  
8 months 
NTproBNP in BPD [51] 
Prospective 
observational 
2010 Jerusalem, 
Israel 
34 preterm <34 weeks 1 year NTproBNP in BPD [52] 
Prospective 
observational 
2012 Ankara, 
Turkey 
67 neonates with TTN 
33 healthy controls 
9 months NTproBNP in TTN [53] 
Prospective 
observational 
2013 Ankara, 
Turkey 
87 neonates with CHD 1 year  
1 month 
BNP in TTN [54] 
Observational 2016 Eskisehir, 
Turkey 
30 neonates with 
perinatal asphyxia 
30 healthy controls 
Not 
mentioned 
TnT and CKMB in 
perinatal asphyxia 
[55] 
Prospective 
observational 
2010 Mansoura, 
Egypt 
25 neonates with 
perinatal asphyxia 
20 healthy controls 
1 year TnT in perinatal 
asphyxia 
[56] 
Observational 2009 Zhejiang, 
China 
31 neonates with severe 
perinatal asphyxia 
31 neonates with mild 
perinatal asphyxia 
30 healthy term 
2 years  
2 months 
TnI in perinatal 
asphyxia 
[57] 
Prospective 
case-control 
observational 
2008 Puducherry, 
India 
30 term with perinatal 
asphyxia 
30 healthy term controls 
Not 
mentioned 
TnT and CKMB in 
perinatal asphyxia 
[58] 
Retrospective 
observational 
2006 Poznan, 
Poland 
21 preterm with perinatal 
asphyxia 
22 term controls 
Not 
mentioned 
TnT and CKMB in 
perinatal asphyxia 
and RD 
[59] 
Prospective 
observational 
2005 Lumpur, 
Malasia 
50 term with perinatal 
asphyxia 
50 healthy term controls 
2 years  
2 months 
TnT and CKMB in 
perinatal asphyxia 
[60] 
Observational 2005 Los 
Angeles, 
USA 
39 term with perinatal 
asphyxia 
44 healthy term controls 
Not 
mentioned 
TnT in perinatal 
asphyxia 
[61] 
Prospective 
observational 
2004 Kocaeli, 
Turkey 
112 neonates with 
perinatal asphyxia 
84 healthy controls 
2 years  
3 months 
TnI and CKMB in 
perinatal asphyxia 
and HIE 
[62] 
Observational 2006 Padova, 
Italy 
13 neonates with 
perinatal asphyxia 
39 healthy controls 
2 years  
5 months 
TnI in perinatal 
asphyxia 
[63] 
Observational 2012 Benin, 
Nigeria 
40 neonates with 
perinatal asphyxia 
30 healthy controls 
1 year TnT in perinatal 
asphyxia 
[64] 
Observational 2014 Benin, 
Nigeria 
40 neonates with 
moderate to severe 
perinatal asphyxia 
1 year TnT and CKMB in 
perinatal asphyxia 
[65] 
Prospective 
observational 
2007 Rome,  
Italy 
29 neonates with 
perinatal asphyxia 
30 healthy controls 
1 year TnT in perinatal 
asphyxia 
[66] 
Prospective 
observational 
2005 Kayseri, 
Turkey 
45 neonates with 
perinatal asphyxia 
15 healthy term controls 
Not 
mentioned 
TnT in perinatal 
asphyxia 
[67] 
Retrospective 
observational 
2012 Norwich, 
UK 
60 neonates with HIE 5 years TnI in HIE [68] 
Prospective 
observational 
2004 Kocaeli, 
Turkey 
54 neonates with HIE 
50 healthy controls 
2 years  
7 months 
TnI in HIE [69] 
Prospective 
observational 
2006 Liverpool, 
UK 
24 neonates with RD 
14 preterm without RD 
 TnT in RD [70] 
Prospective 
observational 
2012 Cairo and 
Minia, 
Egypt 
40 term of diabetic 
mothers 
40 term of non-diabetic 
healthy mothers 
3 years  
2 months 
TnI in Cardiac 
Dysfunction 
[71] 
Nested 
prospective 
cohort 
2006 Richmond, 
USA 
27 neonates 
(cardiovascular substudy 
of the PROPHET trial) 
1 year  
2 months 
TnT in Cardiac 
Dysfunction 
[72] 
Observational 2012 Lublin, 
Poland 
54 neonates with CHD 
29 heathy neonates 
Not 
mentioned 
TnT in CHD [73] 
Prospective 
Cohort 
2005 New York, 
USA 
45 neonates with CHD Not 
mentioned 
TnI in CHD [74] 
Prospective 
observational 
2016 Porto, 
Portugal 
34 neonates with CHD 
20 healthy controls 
1 year  
5 months 
TnI, CKMB and 
Myoglobin in CHD 
[75] 
Observational 2008 Dublin, 
Ireland 
80 preterm <1500g Not 
mentioned 
TnT in PDA [76] 
Prospective 
observational 
2007 Beirut, 
Lebanon 
48 neonates with RD 
116 healthy controls 
9 months TnT in RD [77] 
Prospective 
observational 
2004 Liverpool, 
UK 
49 neonates with RD 
113 healthy controls 
1 year  
1 month 
TnT in RD [78] 
Observational 2001 Liverpool 
UK 
27 neonates with RD 
215 healthy controls 
10 months TnT in RD [79] 
Observational 2000 Padua,  
Italy 
26 preterm <32 weeks 
with RD 
20 preterm without RD 
6 months TnT in RD [80] 
Observational 2006 Catania, 
Italy 
30 ventilated preterm 
with RD 
10 healthy preterm 
Not 
mentioned 
TnI in RD [81] 
  Tn: Troponin; PDA: patent ductus arteriosus; LtR shunts: left-to-right Shunts; CHD: congenital heart defect; PH: pulmonary 
hypertension; RD: respiratory distress; BPD: bronchopulmonary dysplasia; TTN: transient tachypnea of the newborn; HIE: 
hypoxic ischemic encephalopathy 
   
Table 2 Cutoffs proposed for hemodynamically significant patent ductus arteriosus 
Gestational 
age 
Day hsPDA/ 
included (n) 
Proposed cutoff 
value 
AUC Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Reference 
<28 weeks 2 24/67 
550pg/ml BNP 
(for ductus 
intervention) 
0.86 83 76 77 90 [23] 
<30 weeks 1 31/73 900 pg/ml BNP 0.83 54.8 95.2 89.5 74.1 [21] 
<34 weeks 3 23/66 1110 pg/ml BNP 
0.99
7 
100 95.3 - - [20] 
<34 weeks 3 17/52 
123 ng/L BNP 
(for treatment) 
1.00 100 100 - - [29] 
<34 weeks 
7 
(mean) 
14/29 70 pg/ml BNP 0.91 92.9 73.3 77 92 [19] 
<36 weeks 2 20/20 
300 pg/ml BNP 
(for PDA >1.5mm) 
- 
52 
 
100 
 
100 
 
74 
 
[18] 
<37 weeks 2 16/34 283.5 pg/ml BNP - 81.3 100   [22] 
<42 weeks 2 19/75 201.5 pg/ml BNP - 89.5 100 - - [22] 
<32 weeks 1 29/46 
<9854 pg/ml 
NTproBNP 
(for spontaneous 
closure) 
0.86 71.8 100 - - [26] 
<32 weeks 2 12/31 
10 000 pg/ml 
NTproBNP 
(to exclude 
spontaneous closure) 
0.92 89 100 100 87 [30] 
<32 weeks 4 12/31 
5000 pg/ml 
NTproBNP 
(to exclude 
spontaneous closure) 
0.98 91 100 100 94 [30] 
<33 weeks 2 12/35 
10 180 pg/ml 
NTproBNP 
0.96
4 
100 91 86.7 100 [32] 
<34 weeks 2 18/49 
11 395 pg/ml 
NTproBNP 
0.97
8 
100 95 - - [28] 
<34 weeks 3 20/56 
2850 pmol/L 
NTproBNP 
(for clinically 
significant PDA) 
- 90 89 82 90 [27] 
hsPDA: hemodynamically significant patent ductus arteriosus; AUC: area under curve; PPV: positive predictive 
value; NPV: negative predictive value 
 
   
  
Table 3 Cardiac Biomarkers in neonatal pathologies and their clinical relevance 
 BNP/NTproBNP Troponin I/T CKMB Clinical Relevance 
PDA 
↑ 
 
↑  
Diagnosis of PDA and hsPDA 
Individualized therapy and monitoring 
Complications and mortality 
CHD ↑ ↑  
Indicator of myocardial compromise (contractility) a 
Inotropic support after birth b 
PH ↑   
Diagnosis 
Treatment (inhaled NO) 
Mortality  
RD ↑ ↑  
Indicator of myocardial damage a 
Treatment (oxygen, ventilatory and inotropic support) a 
Severity a  
Mortality a 
BPD ↑   
Severity 
Mortality 
PA  ↑ ↑ 
Indicator of myocardial damage 
Treatment (inotropic support) a 
Severity  
Mortality a 
HIE  ↑ ↑ 
Severity a  
Mortality a 
 PDA: Patent Ductus Arteriosus; hsPDA: hemodynamically significant patent ductus arteriosus; CHD: congenital 
heart defect; PH: pulmonary hypertension; RD: respiratory distress; BPD: bronchopulmonary dysplasia; PA: 
perinatal asphyxia; HIE: hypoxic ischemic encephalopathy 
a  Only for Troponin I/T 
b Only for cord blood BNP 
 
 
 373 articles identified through PubMed searching 
 372 articles screened after duplicates removed 
273 articles excluded: 
- 27 did not include a group of only neonates 
- 22 did not focus on pathologies diagnosed after birth 
- 188 did not addressed our outcomes of interest 
- 2 animal studies 
- 34 comments, reviews or case series 
Non access to full text of 5 articles 
94 full-text articles assessed for eligibility 
27 articles excluded: 
- 7 did not include a group of only neonates 
- 20 did not addressed our outcomes of interest 
67 articles selected for data extraction 
Figure 1 Flowchart of the systemic review 
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